Loading…
Makes Nuplazid for Parkinson's-disease psychosis and Daybue for Rett syndrome, with a CNS-focused pipeline.
Makes Nuplazid for Parkinson's-disease psychosis and Daybue for Rett syndrome, with a CNS-focused pipeline.
Sells both drugs in the US through specialty pharmacies, paid prescription by prescription by insurers. Nuplazid, on sale since 2016, carries most of the revenue, and Daybue, launched in 2023, is the newer line. Daybue is licensed from Neuren Pharmaceuticals, to which Acadia pays royalties.
Moat: narrow (IP / patents, regulatory licence). Orphan-drug exclusivity and being first-approved in each indication limit near-term competition.
Headquarters: San Diego, California, US · Founded: 1993 · Employees: 798
Size ACADIA Pharmaceuticals (ACAD) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.66B, the 1402nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $21.23 on 6 Nov 2026.
Performance Over six months the shares fell 5.2%, against +4.1% for the median peer and -1.1% for the United States market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 11.8% over the last twelve months (peer median +8.7%); the operating margin is 7.6% (peer median 15.7%).
Valuation It trades at 21.5× forward earnings against a peer median of 20.8× (8th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.5 points above its cost of capital (9.2% WACC).
Short interest Short interest is 5.3% of the free float (15 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.14B | $1.07B | $958M | $726M | $517M |
| Revenue growth | — | +12% | +32% | +40% | — |
| Gross profit | $1.04B | $972M | $861M | $681M | $507M |
| EBITDA | $98.4M | $117M | $100M | -$67.8M | -$222M |
| Net income | $380M | $391M | $226M | -$61.3M | -$216M |
| Free cash flow | $146M | $105M | $157M | $16.7M | -$114M |
| Capital expenditure | $14.7M | $104M | $523,000 | $40.0M | $0 |
| Total debt | $73.9M | $52.2M | $52.0M | $57.2M | $62.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals ACAD | $3.66B | -5% | +12% | 8% | 21.5× | 16.7% |
| Neurocrine Biosciences NBIX | $16.7B | +8% | +38% | 25% | 18.2× | -1.7% |
| Supernus Pharmaceuticals SUPN | $5.43B | -49% | +16% | 45% | 6.7× | 4.2% |
| Biogen BIIB | $36.7B | +28% | +2% | 17% | 16.8× | 9.4% |
| Jazz Pharmaceuticals Public JAZZ | $15.1B | +4% | +13% | 25% | 8.9× | -3.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ACAD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.4% | +3.1% | 8th highest of 21 |
| 6-month return | -5.2% | +4.1% | 8th lowest of 20 |
| Distance from 52-week high | -31.4% | -23.8% | 6th lowest of 21 |
| Revenue growth (TTM) | +11.8% | +8.7% | 8th highest of 19 |
| Operating margin | 7.6% | 15.7% | 4th lowest of 17 |
| Forward P/E | 21.5× | 20.8× | 8th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 16.7% | 1.1% | 4th most demanding of 15 |
| Growth delivered (Del g) | +19.4% | +9.2% | 5th highest of 15 |
| Hurdle (Req g minus delivered) | -2.7 pp | -11.9 pp | 4th most demanding of 15 |
| ROIC minus cost of capital | +8.5 pp | +4.3 pp | 7th highest of 16 |
| EV / EBITDA | 27.8× | 15.9× | 3rd most expensive of 11 |
| Net debt / EBITDA | -9.0× | 2.3× | least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 21.5× | 16.7% | +19.4% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 4.0× | -4.5% | -1.0% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 14.3× | -2.8% | +10.6% |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.69B | -11% | -10% | 19% | 11.3× | -7.7% | +2.0% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 43.4× | 20.5% | +98.4% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 25.1× | 6.3% | +4.5% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 6.0× | -5.3% | +7.8% |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 19.6× | -2.2% | +12.0% |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 15.6× | -5.2% | +3.2% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% | +5.9% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 22.3× | 1.5% | +12.1% |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.41B | -37% | +33% | 12% | 23.8× | 15.2% | +61.4% |
| Tarsus Pharmaceuticals TARS | United States | $3.38B | +12% | +86% | -10% | n/a | 31.9% | +159.5% |
| Piramal Pharma PPLPHARMA.NS | India | $3.37B | +30% | +9% | 3% | 159.9× | n/a | n/a |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 32.9× | 0.7% | +192.5% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 17.8× | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.35B | +19% | +26% | 13% | n/a | 56.9% | +4.2% |